Valuation: Positron Corporation

Market Cap 5.42Cr 4.74Cr 4.37Cr 4.03Cr 7.59Cr 521.91Cr 7.76Cr 52Cr 21Cr 255.61Cr 20Cr 20Cr 879.93Cr P/E 2024
-11x
P/E 2025 -4.87x
Enterprise Value 5.31Cr 4.64Cr 4.28Cr 3.94Cr 7.43Cr 510.97Cr 7.6Cr 51Cr 20Cr 250.25Cr 20Cr 19Cr 861.48Cr EV / Sales 2024
49.4x
EV / Sales 2025 116x
Free-Float
47.44%
Yield 2024 *
-
Yield 2025 -
1 day+0.41%
1 week-2.08%
Current month-12.23%
1 month-9.34%
3 months-12.70%
6 months-0.72%
Current year-1.20%
1 week 1.43
Extreme 1.43
1.7
1 month 1.43
Extreme 1.43
1.94
Current year 1.43
Extreme 1.43
2.74
1 year 1.27
Extreme 1.27
2.74
3 years 0.87
Extreme 0.87
2.94
5 years 0.07
Extreme 0.0682
2.94
10 years 0
Extreme 0
2.94
Manager TitleAgeSince
President 53 27/02/2018
Sales & Marketing - 24/06/2022
Corporate Officer/Principal 40 25/05/2018
Director TitleAgeSince
Chairman 53 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+0.41%-2.08%+13.21%+3.12% 5.42Cr
-1.21%+1.26%-13.71%-18.30% 1.34TCr
-6.37%-15.89%+41.04%-8.81% 386.25Cr
-0.76%-0.17%+71.16%+109.07% 124.03Cr
-4.45%-0.26%-35.24%-60.78% 118.4Cr
-4.35%-2.94%-40.50%-46.45% 109.43Cr
-3.75%+6.82%-42.81% - 94Cr
-8.55%-20.41%+61.00%+90.38% 49Cr
+5.01%+12.02%+47.47% - 34Cr
+0.89%+4.34%-57.43%+243.20% 27Cr
Average -2.28%-0.32%+4.42%+38.93% 228.18Cr
Weighted average by Cap. -2.52%-0.29%-1.37%-7.29%

Financials

2024 2025
Net sales 6L 5L 5L 4L 8L 5.66Cr 8L 56.63L 22.27L 2.77Cr 22.06L 21.58L 9.54Cr 5L 4L 4L 3L 6L 4.44Cr 7L 44.48L 17.49L 2.18Cr 17.33L 16.95L 7.49Cr
Net income -23.79L -20.79L -19.19L -17.68L -33.33L -23Cr -34.07L -2.29Cr -90.19L -11Cr -89.35L -87.39L -39Cr -1.06Cr -92.66L -85.51L -78.82L -1.49Cr -102.11Cr -1.52Cr -10Cr -4.02Cr -50Cr -3.98Cr -3.89Cr -172.16Cr
Net Debt 14.24L 12.45L 11.49L 10.59L 19.96L 14Cr 20.4L 1.37Cr 54L 6.72Cr 53.49L 52.32L 23Cr -11.36L -10L -9L -8L -15.92L -11Cr -16.27L -1.1Cr -43.07L -5.36Cr -42.67L -41.73L -18Cr
Logo Positron Corporation
Positron Corporation is a medical technology company focused to advancing the Positron Emission Tomography (PET) imaging modality through the development, manufacturing, and commercialization of its PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems along with providing comprehensive clinical services to nuclear medicine healthcare providers across North America. The Company specializes in the field of cardiac PET imaging, the gold standard in cardiac diagnostics. The Company’s imaging portfolio includes dedicated PET and 3D PET-CT 64-Slice systems, both designed to expand access to advanced molecular imaging. Additionally, it is preparing to introduce its 4D PET-CT 64-Slice scanner in nuclear cardiology. Its products, Attrius PET and NeuSight PET-CT 64- Slice scanner, provide a molecular imaging solution, enabling healthcare providers with diagnostic accuracy for cardiac and oncologic applications.
Employees
10
Date Price Change Volume
17/26/17 $1.650 +0.41% 27,059
16/26/16 $1.643 -3.34% 2,125
15/26/15 $1.700 +9.68% 19,501
14/26/14 $1.550 -6.06% 30,756
13/26/13 $1.650 -2.08% 12,429
  1. Stock Market
  2. Stocks
  3. POSC Stock